Immunine (Human Coagulation Factor Ix)

Human Coagulation Factor IX supplied by Immunine binds to activated factor VIII on phospholipid surfaces, forming the tenase complex that converts factor X to factor Xa. This re‑establishes the intrinsic coagulation cascade, leading to thrombin generation and stable fibrin clot formation, thereby correcting the bleeding tendency in hemophilia B.

The dose of Immunine is individualized by the prescribing clinician based on the patient’s weight, baseline factor IX activity, severity of the bleed or surgical procedure, and target trough levels. Dosing calculations follow established hemophilia guidelines and are adjusted according to clinical response and laboratory monitoring.

Safety data for Immunine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should weigh potential benefits against unknown risks, and use the drug only if clearly indicated. Breastfeeding mothers should consult their healthcare provider before use.

To order Immunine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Immunine is a plasma‑derived human factor IX concentrate, whereas alternative products may be recombinant or extended‑half‑life formulations. Clinical efficacy is comparable for bleeding control, but differences exist in half‑life, infusion frequency, and immunogenicity risk. Choice of product depends on patient‑specific factors, treatment goals and physician preference.

Immunine must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to infusion, the solution may be allowed to reach room temperature, but any visible particles or discoloration require disposal.

Immunine is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate is determined by the prescribing clinician and may be adjusted based on patient tolerance. Monitoring of vital signs and observation for infusion‑related reactions are recommended during and after administration.

The most serious risks include severe allergic or anaphylactic reactions, the development of neutralizing antibodies (inhibitors) that reduce efficacy, and thromboembolic events such as deep‑vein thrombosis. Patients should be educated to report any signs of rash, difficulty breathing, sudden pain, swelling or unexplained bruising promptly.

Immunine is contraindicated in individuals with known hypersensitivity to human plasma‑derived factor IX products or any of the excipients. Patients with a history of severe allergic reactions to factor concentrates should avoid use. Additionally, it should be used with caution in those with uncontrolled cardiovascular disease until risk is assessed.